Evaluation of new 99mTc(CO)3 + radiolabeled glycylglycine In Vivo

Basit Öğe Kaydı
dc.contributor.authorŞenışık A.M.
dc.contributor.authorİçhedef Ç.
dc.contributor.authorKılçar A.Y.
dc.contributor.authorUçar E.
dc.contributor.authorArı K.
dc.contributor.authorParlak Y.
dc.contributor.authorTeksöz S.
dc.date.accessioned2021-05-03T20:51:57Z
dc.date.available2021-05-03T20:51:57Z
dc.date.issued2019
dc.description.abstractBackground: Peptide-based agents are used in molecular imaging due to their unique properties, such as rapid clearance from the circulation, high affinity and target selectivity. Many of the radiolabeled peptides have been clinically experienced with diagnostic accuracy. The aim of this study was to investigate in vivo biological behavior of [99mTc(CO)3(H2O)3]+ radiolabeled glycylglycine (GlyGly). Methods: Glycylglycine was radiolabeled with a high radiolabeling yield of 94.69±2%, and quality control of the radiolabeling process was performed by thin layer radiochromatography (TLRC) and High-Performance Liquid Radiochromatography (HPLRC). Lipophilicity study for radiolabeled complex (99mTc(CO)3-Gly-Gly) was carried out using solvent extraction. The in vivo evaluation was performed by both biodistribution and SPECT imaging. Results: The high radiolabelling yield of 99mTc(CO)3-GlyGly was obtained and verified by TLRC and HPLRC as well. According to the in vivo results, SPECT images and biodistribution data are in good accordance. The excretion route from the body was both hepatobiliary and renal. Conclusion: This study shows that 99mTc(CO)3-GlyGly has the potential to be used as a peptide-based imaging agent. Further studies, 99mTc(CO)3-GlyGly can be performed on tumor-bearing animals. © 2019 Bentham Science Publishers.en_US
dc.description.sponsorshipEge Ãœniversitesi: 2012 NBE 004 Firat University Scientific Research Projects Management Unit, FÃœBAPen_US
dc.description.sponsorshipThis study was financially supported by the Ege University Scientific Research Project numbered 2012 NBE 004 (Bornova Izmir, Turkey). The authors thank Marylou Doganavsargil for English editing of the manuscript.en_US
dc.description.sponsorshipThis study was financially supported by the Ege University Scientific Research Project numbered 2012 NBE 004 (Bornova Izmir, Turkey).en_US
dc.identifier.doi10.2174/1871520619666190404154723en_US
dc.identifier.endpage1387en_US
dc.identifier.issn1871-5206
dc.identifier.issue11en_US
dc.identifier.pmid30947676en_US
dc.identifier.scopus2-s2.0-85075625899en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1382en_US
dc.identifier.urihttps://doi.org/10.2174/1871520619666190404154723
dc.identifier.urihttps://hdl.handle.net/11454/70981
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publishersen_US
dc.relation.ispartofAnti-Cancer Agents in Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiodistribution studiesen_US
dc.subjectGlycylglycineen_US
dc.subjectIn vivoen_US
dc.subjectRadiolabelingen_US
dc.subjectSPECT imagingen_US
dc.subjectTechnetium tricarbonyl coreen_US
dc.titleEvaluation of new 99mTc(CO)3 + radiolabeled glycylglycine In Vivoen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu